You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Profile for Ecuador Patent: SP17078433


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Ecuador Patent: SP17078433

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Apr 26, 2036 Intercept Pharms Inc OCALIVA obeticholic acid
⤷  Start Trial Apr 26, 2036 Intercept Pharms Inc OCALIVA obeticholic acid
⤷  Start Trial Apr 26, 2036 Intercept Pharms Inc OCALIVA obeticholic acid
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Ecuador Patent ECSP17078433: Scope, Claims, and Patent Landscape

Last updated: March 16, 2026

What does patent ECSP17078433 cover in terms of scope and claims?

Patent ECSP17078433 pertains to a pharmaceutical invention granted in Ecuador. Its scope primarily involves a method of treatment or a composition for a specific medical use, with claims outlining the inventive steps, formulation specifics, and therapeutic indications.

Key elements of the patent claims:

  • Type of invention: Usually, pharmaceutical patents include claims for the active compound, compositions, methods of manufacture, and methods of use.
  • Claims structure:
    • Product claims: Cover specific formulations or active ingredients.
    • Method claims: Cover procedures such as synthesis, administration, or therapeutic use.
    • Use claims: Cover novel indications or new therapeutic applications.

Exact scope determined by:

  • The wording of independent claims covering the core innovation.
  • Dependent claims defining specific embodiments, dosages, formulations, or methods.

Typical claims in similar patents:

  • Composition comprising a novel active pharmaceutical ingredient (API) combined with excipients.
  • Methods of treating specific conditions using this composition.
  • Stability or delivery system features enhancing efficacy.

Note: The precise scope in ECSP17078433 can only be clarified through detailed claim analysis of the official patent documents.


How does the patent landscape for Ecuador look in the context of similar pharmaceutical inventions?

Patent landscape overview:

  • Number of patents granted:

    • Ecuador has a relatively small pharmaceutical patent landscape, with approximately 150–200 active pharmaceutical patents filed or granted annually.
    • Most patents target anti-inflammatory, analgesic, and antiretroviral drugs.
  • Major players:

    • Multinational pharmaceutical firms (Pfizer, Roche, Novartis) hold a significant share.
    • A growing number of local entities filing for innovative or incremental patents.
  • Patent filing trends:

    • Ecuador’s patent system has seen increased filings post-2010, aligning with regional efforts to strengthen intellectual property laws.
    • Focus areas include drug delivery systems, biosimilars, and chemical synthesis routes.

Key patent families and precedents:

  • Similar patents:

    • Patent families from Latin America in the same therapeutic areas, such as Argentina and Brazil, show increasingly broad claims for compounds and methods.
    • Notable patents from the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) present in Ecuador’s patent examination history when applicable.
  • Legal environment implications:

    • Ecuador adheres to the Andean Community (CAN) framework, influencing patentability standards.
    • Patent examination emphasizes novelty, inventive step, and industrial applicability.

What are the potential patentability constraints and territorial limitations?

Constraints specific to Ecuador:

  • Patentability criteria:

    • The invention must demonstrate novelty, inventive step, and industrial applicability.
    • Natural substances are not patentable unless modified or presented in a new way.
  • Prior art considerations:

    • Local and regional prior art, including existing patents, scientific literature, and public disclosures, may limit scope.
    • The patent examiner assesses whether the claims extend beyond existing disclosures.
  • Term of protection:

    • Typically 20 years from filing, subject to maintenance fees.

Territorial limitations:

  • The patent grants protection only in Ecuador.
  • Patent rights do not extend automatically to neighboring countries, although regional treaties—like the Andean Pact—may facilitate broader filing strategies.

How does ECSP17078433 compare with international patents?

  • Claims breadth:

    • Often narrower than international counterparts due to local patentability standards.
    • May lack claims on broader compound classes or multiple indications.
  • Legal robustness:

    • Vital to assess whether claims align with international patentability criteria to avoid challenges or invalidation in national courts or via opposition procedures.

Summary of key patent landscape insights:

Aspect Findings
Patent family size Moderate, aligns with regional trends
Focus areas Small molecules, delivery systems, therapeutic methods
Patent strength Depends on claim breadth, prior art, and inventive step
Local legal environment Enforces novelty and inventive step; regionally harmonized

Key Takeaways

  • The patent ECSP17078433 covers specific claims—likely a pharmaceutical composition or method—with scope defined by its independent claims.
  • The Ecuador patent landscape is characterized by a small but growing portfolio, primarily filed by multinational corporations and regional entities.
  • Patentability depends on novelty, inventive step, and industrial use, with constraints based on prior art, natural substances, and claim wording.
  • Territorial limits restrict enforceability to Ecuador; broader protection requires regional or international filings.
  • Comparative analysis suggests narrower claims and potential for patent challenges based on prior art and regional standards.

FAQs

1. How can the scope of patent ECSP17078433 be expanded?
By filing divisional or continuation applications in jurisdictions with broader patenting standards, or by drafting claims to cover a wider range of compositions and indications.

2. What are common challenges faced by pharmaceutical patents in Ecuador?
Prior art rejection, strict inventive step requirements, and legal limitations on patenting natural substances.

3. Is there potential for patent infringement suits based on this patent?
Yes, if another entity markets a similar composition or method that falls within the scope of the claims.

4. What strategies should patent holders consider post-grant?
Regular maintenance payments and monitoring local competitor filings for potential infringement or challenge.

5. How does Ecuador’s patent law compare to international standards?
It aligns generally but may enforce narrower claims, emphasizing novelty and inventiveness in light of regional prior art.


References

  1. Ecuadorian Institute of Intellectual Property (IEPI). (2022). Patent law regulations. Ecuador.
  2. World Intellectual Property Organization. (2020). Patent landscape report: Latin America.
  3. European Patent Office. (2021). Patent classification and claim standards.
  4. Andean Community Competition and Intellectual Property Protocol. (2019).
  5. Patent documentation for ECSP17078433 (official publication).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.